July 1，Yangsen Pharmaceutical Announcement，FDA has approved XARELTO (Levishabane) to prevent deep venous thrombosis in patients with knee or hip joint replacement.，The latter may cause pulmonary embolism。XARELTO is a oral anticoagulation medicine，10mg tablets，Application once a day。

Patients with knee joint replacement should continue to take XARELTO 12 days，Patients with hip joint replacement should take stake online sports bettingstake sports betting appthis medicine for 35 days。

Yang Sen pointed out，The key data of the phase III clinical development plan of xralto III shows the significant efficacy advantage of Lidiastan，Whether in the direct comparison with Yinoidin，Still will be extended (5 weeks) Ledhabane with short -term use (2 weeks) in the response to the response of the reinforcement heparin sequence placement.。In these experiments，Levarhabane and Yinuo heparin show a similar safety spectrum，Among them, the incidence of major bleeding is low。

Bleeding is the most common adverse reaction among patients who received XARELTO treatment。